2016ASH-III期 LyMa实验-移植后利妥昔单抗维持可延长年轻套细胞淋巴瘤患者的生存.ppt

Phase III LyMa Trial: Post-ASCT Rituximab Maintenance Increases Survival for Younger Patients With Mantle Cell Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH 2016*; December 3-6, 2016; San Diego, California *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. This activity is supported by educational grants from Amgen, Celgene Corporation, Incyte, Merck, and Seattle Genetics. LyMa: Background After responding to initial therapy for